Can You Hear That Whistle Blow? Sales Force Reductions Come with Risks
This article was originally published in RPM Report
Executive Summary
Pfizer's big sales force cuts mark the beginning of a disarmament in sales infrastructure across the pharmaceutical industry. That means a lot of sales reps will be out of work-and looking for payback.
You may also be interested in...
The "Super FDA": State Attorneys General Flex Their Muscle in Pharma Enforcement
States have become more aggressive in pursuing pharma for health care fraud. They are building stronger cases by teaming up with each other and the federal government to push companies to accept more onerous restrictions on their business practices.States have become more aggressive in pursuing pharma for health care fraud. They are building stronger cases by teaming up with each other and the federal government to push companies to accept more onerous restrictions on their business practices.
Bextra Settlement Coming Soon: Industry Should Brace for Impact
Record setting $2.3 billion payment is afterthought in context of Pfizer/Wyeth merger, but the Bextra and recent Zyprexa settlement will have far-reaching implications. In economic terms, the first two cases of 2009 exceed the total recoveries of the last 13 pharma marketing settlements. But the big impact may be political: the cases involve a volatile mix of marketing abuses and drug safety
The "Super FDA": State Attorneys General Flex Their Muscle in Pharma Enforcement
States have become more aggressive in pursuing pharma for health care fraud. They are building stronger cases by teaming up with each other and the federal government to push companies to accept more onerous restrictions on their business practices.States have become more aggressive in pursuing pharma for health care fraud. They are building stronger cases by teaming up with each other and the federal government to push companies to accept more onerous restrictions on their business practices.